Indications for Active Case Searches and Intravenous Alpha-1 Antitrypsin Treatment for Patients With Alpha-1 Antitrypsin Deficiency Chronic Pulmonary Obstructive Disease: An Update;Actualización sobre indicaciones de búsqueda activa de casos y tratamiento con alfa-1 antitripsina por vía intravenosa en pacientes con enfermedad pulmonar obstructiva crónica asociada a déficit de alfa-1 antitripsina

Archivos de Bronconeumologia

Volumn 51, Issue 4, 2015, Pages 185-192

  Casas, Francisco ^a   Blanco, Ignacio ^b   Martínez, María Teresa ^c   Bustamante, Ana ^d   Miravitlles, Marc ^e   Cadenas, Sergio ^f   Hernández, José M ^g   Lázaro, Lourdes ^h   Rodríguez, Esther ^e   Rodríguez Frías, Francisco ^e   Torres, María ⁱ   Lara, Beatriz ^j  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b Respira SEPAR   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL SIERRALLANA   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^g Hospital General de La Palma   (Spain)

^h HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

ⁱ UNIVERSITY OF VIGO   (Spain)

^j HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

more..

Author keywords

Alpha 1 antitrypsin deficiency; Diagnoses; Spanish Registry of Patients with alpha 1 antitrypsin deficiency; Treatment

Indexed keywords

ALPHA 1 ANTITRYPSIN; PLACEBO;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CASE STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; DRUG INDICATION; EMPHYSEMA; GENOTYPE; HUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PROTEIN BLOOD LEVEL; SCREENING TEST; ALPHA 1-ANTITRYPSIN DEFICIENCY; BLOOD; CLINICAL TRIAL (TOPIC); COMPLICATION; DOUBLE BLIND PROCEDURE; ENZYME REPLACEMENT; EVIDENCE BASED MEDICINE; GENETIC SCREENING; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL SOCIETY; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; SPAIN; TREATMENT OUTCOME; ALLELE; DISEASE COURSE; DISEASE SEVERITY; MORTALITY; QUALITATIVE ANALYSIS; SYSTEMATIC REVIEW; TREATMENT INDICATION;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; ENZYME REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; GENETIC TESTING; GENOTYPE; HUMANS; INFUSIONS, INTRAVENOUS; META-ANALYSIS AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; SOCIETIES, MEDICAL; SPAIN; TREATMENT OUTCOME;

EID: 84928882668     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2014.12.006     Document Type: Article

References (111)

1. American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2003, 168:818-900.
2. Stoller J.K., Aboussouan L.S. A review of α1-antitrypsin deficiency. Am J Respir Crit Care Med 2012, 185:246-259.
3. Vidal R., Blanco I., Casas F., Jardí R., Miravitlles M. Normativa SEPAR: diagnóstico y tratamiento del déficit de alfa-1-antitripsina. Arch Bronconeumol 2006, 42:645-659. Comité del Registro Nacional de Pacientes con Déficit de Alfa-1-Antitripsina.
4. Dirksen A., Piitulainen E., Parr D.G., Deng C., Wencker M., Shaker S.B., et al. Exploring the role of CT densitometry: A randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009, 33:1345-1353.
5. Stockley R.A., Parr D.G., Piitulainen E., Stolk J., Stoel B.C., Dirksen A. Therapeutic efficacy of -1 antitrypsin augmentation therapy on the loss of lung tissue: An integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 2010, 11:136-144.
6. Parr D.G., Guest P.G., Reynolds J.H., Dowson L.J., Stockley R.A. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2007, 176:1215-1221.
7. Eden E., Holbrook J.T., Brantly M.L., Turino G.M., Wise R.A. Prevalence of alpha-1 antitrypsin deficiency in poorly controlled asthma -results from the ALA-ACRC low-dose theophylline trial. J Asthma 2007, 44:605-608.
8. Mascalchi M., Diciotti S., Sverzellati N., Camiciottoli G., Ciccotosto C., Falaschi F., et al. Low agreement of visual rating for detailed quantification of pulmonary emphysema in whole-lung CT. Acta Radiol 2012, 53:53-60.
9. Hogarth D.K., Rachelefsky G. Screening and familial testing of patients for alpha 1-antitrypsin deficiency. Chest 2008, 133:981-988.
10. Gøtzsche P.C., Johansen H.K. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev 2010, CD007851. (7).
11. Gøtzsche P.C., Johansen H.K. Intravenous alpha-1 antitrypsin augmentation therapy: Systematic review. Dan Med Bull 2010, 57:A4175.
12. Chapman K.R., Stockley R.A., Dawkins C., Wilkes M.M., Navickis R.J. Augmentation therapy for alpha1 antitrypsin deficiency: A meta-analysis. COPD 2009, 6:177-184.
13. Marciniuk D.D., Hernandez P., Balter M., Bourbeau J., Chapman K.R., Ford G.T., et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline. Can Respir J 2012, 19:109-116. Canadian Thoracic Society COPD Clinical Assembly Alpha-1 Antitrypsin Deficiency Expert Working Group.
14. Gadek J.E., Klein H.G., Holland P.V., Crystal R.G. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981, 68:1158-1165.
15. From the NIH: Intravenous replacement therapy for patients with severe alpha 1-antitrypsin deficiency. JAMA. 1982, 248:1693.
16. Gadek J.E., Crystal R.G. Experience with replacement therapy in the destructive lung disease associated with severe alpha-1-antitrypsin deficiency. Am Rev Respir Dis 1983, 127:S45-S46.
17. Hutchison D.C., Tobin M.J., Cook P.J. Alpha 1 antitrypsin deficiency: clinical and physiological features in heterozygotes of Pi type SZ. A survey by the British Thoracic Association. Br J Dis Chest 1983, 77:28-34.
18. Wewers M.D., Casolaro M.A., Sellers S.E., Swayze S.C., McPhaul K.M., Wittes J.T., et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987, 316:1055-1062.
19. Hubbard R.C., Sellers S., Czerski D., Stephens L., Crystal R.G. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA 1988, 260:1259-1264.
20. Schmidt E.W., Rasche B., Ulmer W.T., Konietzko N., Becker M., Fallise J.P., et al. Replacement therapy for alpha-1-protease inhibitor deficiency in PiZ subjects with chronic obstructive lung disease. Am J Med 1988, 84:63-69.
21. Eriksson S. Replacement therapy in alpha 1-antitrypsin deficiency. J Intern Med 1989, 225:69-72.
22. Eriksson S., Wu M.C. Aspects of treatment in alpha 1-antitrypsin deficiency: Insights derived from a Swedish PiZZ series. Eur Respir J Suppl 1990, 9:39s-43s.
23. Vidal R., Miravitlles M., de Gracia X., Gallego B., Morell F. Replacement therapy of emphysema caused by alpha 1-antitrypsin deficiency. Med Clin (Barc) 1991, 96:180-182.
24. Hay J.W., Robin E.D. Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease. Am J Public Health 1991, 81:427-433.
25. Barker A.F. Alpha 1-antitrypsin-deficiency-related emphysema. J Am Board Fam Pract 1992, 5:489-493.
26. Current status of alpha-1-antitrypsin replacement therapy: Recommendations for the management of patients with severe hereditary deficiency. Ad Hoc Committee on Alpha-1-Antitrypsin Replacement Therapy of the Standards Committee, Canadian Thoracic Society. CMAJ 1992, 146:841-844. Ad Hoc Committee on alpha-1 antitrypsin replacement therapy of the Standards Committee, Canadian Thoracic Society.
27. Burdon J., Cook L., Holmes P., Janus E., Watts S. Alpha-1-antitrypsin replacement therapy -an early Australian experience. Aust N Z J Med 1992, 22:498-499.
28. Cammarata S.K., Stone C.L., Carey J.L., Eichenhorn M.S. Failure to achieve adequate serum levels with monthly replacement therapy in alpha 1-antitrypsin deficiency. Chest 1994, 106:651-652.
29. Miravitlles M., Vidal R., Torrella M., Bofill J.M., Cotrina M., de Gracia J. Evaluation of replacement therapy in emphysema caused by alpha 1-antitrypsin deficiency. Arch Bronconeumol 1994, 30:479-484.
30. Bhagat R., Swystun V.A., Cockcroft D.W. Clinical trials needed for alpha 1-antitrypsin replacement therapy. Chest 1995, 108:586-587.
31. Manresa F. The evolution of the replacement treatment of emphysema due to alpha 1-antitrypsin deficiency. Arch Bronconeumol 1995, 31:371-372.
32. Gadek J.E., Pacht E.R. Pathogenesis of hereditary emphysema and replacement therapy for alpha 1-antitrypsin deficiency. Insight into the more common forms of emphysema. Chest 1996, 110:248s-250s.
33. King M.A., Stone J.A., Diaz P.T., Mueller C.F., Becker W.J., Gadek J.E. Alpha 1-antitrypsin deficiency: evaluation of bronchiectasis with CT. Radiology 1996, 199:137-141.
34. Turino G.M., Barker A.F., Brantly M.L., Cohen A.B., Connelly R.P., Crystal R.G., et al. Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. Am J Respir Crit Care Med 1996, 154:1718-1725. Alpha 1-Antitrypsin Deficiency Registry Study Group.
35. Alpha 1-antitrypsin deficiency: Memorandum from a WHO meeting. Bull World Health Organ 1997, 75:397-415.
36. Hutchison D.C., Hughes M.D. Alpha-1-antitrypsin replacement therapy: Will its efficacy ever be proved. Eur Respir J 1997, 10:2191-2193.
37. Seersholm N., Wencker M., Banik N., Viskum K., Dirksen A., Kok-Jensen A., et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997, 10:2260-2263.
38. Miravitlles M. ¿ Deberíamos administrar tratamiento sustitutivo a los pacientes con déficit de alfa-1 antitripsina?. Arch Bronconeumol 1998, 34:109-111.
39. Miravitlles M., Vidal R., Barros-Tizón J.C., Bustamante A., España P.P., Casas F., et al. Usefulness of a national registry of alpha-1-antitrypsin deficiency. The Spanish experience. Respir Med 1998, 92:1181-1187.
40. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med 1998, 158:49-59. The Alpha-1-Antitrypsin Deficiency Registry Study Group.
41. Wencker M., Banik N., Buhl R., Seidel R., Konietzko N. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen(WATL)-alpha1-AT-study group. Eur Respir J 1998, 11:428-433.
42. Ma S., Lin Y.Y., He J., Rouhani F.N., Brantly M., Turino G.M. Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation. COPD 2013, 10:473-481.
43. Köhnlein T., Klein H., Welte T. Alpha 1-protease inhibitor deficiency. Diagnosis, follow-up and therapy options. Med Klin (Munich) 1999, 94:371-376.
44. Stoller J.K., Brantly M., Fleming L.E., Bean J.A., Walsh J. Formation and current results of a patient-organized registry for alpha(1)-antitrypsin deficiency. Chest 2000, 118:843-848.
45. Schluchter M.D., Stoller J.K., Barker A.F., Buist A.S., Crystal R.G., Donohue J.F., et al. Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 2000, 161:796-801.
46. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: A new hypothesis with supporting data. Chest 2000, 118:1480-1485.
47. Alkins S.A., O'Malley P. Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis. Chest 2000, 117:875-880.
48. Cuvelier A., Muir J.F., Hellot M.F., Benhamou D., Martin J.P., Bénichou J., et al. Distribution of alpha(1)-antitrypsin alleles in patients with bronchiectasis. Chest 2000, 117:415-419.
49. Seersholm N., Wilcke J.T., Kok-Jensen A., Dirksen A. Risk of hospital admission for obstructive pulmonary disease in alpha(1)-antitrypsin heterozygotes of phenotype PiMZ. Am J Respir Crit Care Med 2000, 161:81-84.
50. Abboud R.T., Ford G.T., Chapman K.R. Alpha1-antitrypsin deficiency: A position statement of the Canadian Thoracic Society. Can Respir J 2001, 8:81-88. Standards Committee of the Canadian Thoracic Society.
51. Dowson L.J., Guest P.J., Hill S.L., Holder R.L., Stockley R.A. High-resolution computed tomography scanning in alpha1-antitrypsin deficiency: Relationship to lung function and health status. Eur Respir J 2001, 17:1097-1104.
52. Sansom M.E., Ferry B.L., Sherrell Z.P., Chapel H.M. A preliminary assessment of alpha-1 antitrypsin S and Z deficiency allele frequencies in common variable immunodeficiency patients with and without bronchiectasis. Clin Exp Immunol 2002, 130:489-494.
53. Wencker M., Fuhrmann B., Banik N., Konietzko N. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen. Longitudinal follow-up of patients with alpha (1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 2001, 119:737-744.
54. Wencker M., Marx A., Konietzko N., Schaefer B., Campbell E.J. Screening for alpha1-Pi deficiency in patients with lung diseases. Eur Respir J 2002, 20:319-324.
55. Stockley R.A., Bayley D.L., Unsal I., Dowson L.J. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2002, 165:1494-1498.
56. Miravitlles M., Vilà S., Torrella M., Balcells E., Rodríguez-Frías F., de la Roza C., et al. Influence of deficient alpha1-anti-trypsin phenotypes on clinical characteristics and severity of asthma in adults. Respir Med 2002, 96:186-192.
57. Stoller J.K., Fallat R., Schluchter M.D., O'Brien R.G., Connor J.T., Gross N., et al. Augmentation therapy with alpha1-antitrypsin: Patterns of use and adverse events. Chest 2003, 123:1425-1434.
58. Dawkins P.A., Dowson L.J., Guest P.J., Stockley R.A. Predictors of mortality in alpha1-antitrypsin deficiency. Thorax 2003, 58:1020-1026.
59. Mullins C.D., Wang J., Stoller J.K. Major components of the direct medical costs of alpha1-antitrypsin deficiency. Chest 2003, 124:826-831.
60. Gildea T.R., Shermock K.M., Singer M.E., Stoller J.K. Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2003, 167:1387-1392.
61. Hersh C.P., Dahl M., Ly N.P., Berkey C.S., Nordestgaard B.G., Silverman E.K. Chronic obstructive pulmonary disease in a1-antitrypsin PI MZ heterozygotes: A meta-analysis. Thorax 2004, 59:843-849.
62. Ranes J., Stoller J.K. A review of alpha-1 antitrypsin deficiency. Semin Respir Crit Care Med 2005, 26:154-166.
63. Abboud R.T., Ford G.T., Chapman K.R. Emphysema in alpha1-antitrypsin deficiency: Does replacement therapy affect outcome?. Treat Respir Med 2005, 4:1-8.
64. Shermock K.M., Gildea T.R., Singer M., Stoller J.K. Cost-effectiveness of population screening for alpha-1 antitrypsin deficiency: A decision analysis. COPD 2005, 2:411-418.
65. Stocks J.M., Brantly M., Pollock D., Barker A., Kueppers F., Strange C., et al. Multi-center study: The biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira. COPD 2006, 3:17-23.
66. Soy D., de la Roza C., Lara B., Esquinas C., Torres A., Miravitlles M. Alpha-1-antitrypsin deficiency: Optimal therapeutic regimen based on population pharmacokinetics. Thorax 2006, 61:1059-1064.
67. Vidal R., Padullés N., Sala F., Jardí R., Rodríguez F., Montoro J.B. Pharmacokinetics of alpha1-antitrypsin replacement therapy in severe congenital emphysema. Arch Bronconeumol 2006, 42:553-556.
68. Strange C., Stoller J.K., Sandhaus R.A., Dickson R., Turino G. Results of a survey of patients with alpha-1 antitrypsin deficiency. Respiration 2006, 73:185-190.
69. Abusriwil H., Stockley R.A. Alpha-1-antitrypsin replacement therapy: Current status. Curr Opin Pulm Med 2006, 12:125-131.
70. Van Veen I.H., ten Brinke A., van der Linden A.C., Rabe K.F., Bel E.H. Deficient alpha-1-antitrypsin phenotypes and persistent airflow limitation in severe asthma. Respir Med 2006, 100:1534-1539.
71. De Serres F.J., Blanco I., Fernández-Bustillo E. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: Evidence supporting targeted screening. COPD 2006, 3:133-139.
72. Hericks A.J., Bhat A. An overview of alpha-1 antitrypsin deficiency. Mo Med 2007, 104:255-259.
73. Mordwinkin N.M., Louie S.G. Aralast: An alpha 1-protease inhibitor for the treatment of alpha-antitrypsin deficiency. Expert Opin Pharmacother 2007, 8:2609-2614.
74. Lara B., de la Roza C., Vilà S., Vidal R., Miravitlles M. Development and results of the Spanish registry of patients with alpha-1-antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2007, 2:393-398.
75. Wood A.M., Stockley R.A. Alpha one antitrypsin deficiency: From gene to treatment. Respiration 2007, 74:481-492.
76. Russi E.W. Alpha-1 antitrypsin: Now available, but do we need it. Swiss Med Wkly 2008, 138:191-196.
77. Aboussouan L.S., Stoller J.K. Detection of alpha-1 antitrypsin deficiency: A review. Respir Med 2009, 103:335-341.
78. Petrache I., Hajjar J., Campos M. Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. Biologics 2009, 3:193-204.
79. Sandhaus R.A. Augmentation therapy in alpha-1 antitrypsin deficiency. COPD 2009, 6:147-148.
80. Silverman E.K., Sandhaus R.A. Alpha1-antitrypsin deficiency. N Engl J Med 2009, 360:2749-2757.
81. Stoller J.K., Fallat R., Schluchter M.D., O'Brien R.G., Connor J.T., Gross N., et al. Augmentation therapy with alpha1-antitrypsin: Patterns of use and adverse events. Chest 2009, 136(5 Suppl):e30.
82. Kalsheker N.A. Alpha1-antitrypsin deficiency: Best clinical practice. J Clin Pathol 2009, 62:865-869.
83. Tonelli A.R., Rouhani F., Li N., Schreck P., Brantly M.L. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Int J Chron Obstruct Pulmon Dis 2009, 4:443-452.
84. Dawkins P.A., Dawkins C.L., Wood A.M., Nightingale P.G., Stockley J.A., Stockley R.A. Rate of progression of lung function impairment in alpha1-antitrypsin deficiency. Eur Respir J 2009, 33:1338-1344.
85. McCarthy C., Dimitrov B.D. Augmentation therapy for alpha-1 antitrypsin deficiency -not enough evidence to support its use yet!. COPD 2010, 7:234.
86. Kaplan A., Cosentino L. Alpha1-antitrypsin deficiency: Forgotten etiology. Can Fam Physician 2010, 56:19-24.
87. Banauch G.I., Brantly M., Izbicki G., Hall C., Shanske A., Chavko R., et al. Accelerated spirometric decline in New York City firefighters with a1-antitrypsin deficiency. Chest 2010, 138:1116-1124.
88. Stockley R.A. Emerging drugs for alpha-1-antitrypsin deficiency. Expert Opin Emerg Drugs 2010, 15:685-694.
89. Tonelli A.R., Brantly M.L. Augmentation therapy in alpha-1 antitrypsin deficiency: Advances and controversies. Ther Adv Respir Dis 2010, 4:289-312.
90. Lara B. COPD and alpha-1-antitrypsin deficiency. Arch Bronconeumol 2010, 46:2-8.
91. Sandhaus R.A. Alpha-1 antitrypsin deficiency: Whom to test, whom to treat. Semin Respir Crit Care Med 2010, 31:343-347.
92. Sørheim I.C., Bakke P., Gulsvik A., Pillai S.G., Johannessen A., Gaarder P.I., et al. α1-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest 2010, 138:1125-1132.
93. Kueppers F. The role of augmentation therapy in alpha-1 antitrypsin deficiency. Curr Med Res Opin 2011, 27:579-588.
94. Dickens J.A., Lomas D.A. Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy Insights from the study of disease pathogenesis. Drug Des Devel Ther 2011, 5:391-405.
95. Rodriguez-Frías F., Miravitlles M., Vidal R., Camos S., Jardí R. Rare alpha-1-antitrypsin variants: Are they really so rare. Ther Adv Respir Dis 2012, 6:79-85.
96. Barros-Tizón J.C., Torres M.L., Blanco I., Martínez M.T. Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy. Ther Adv Respir Dis 2012, 6:67-78. Investigators of the rEXA study group.
97. Miravitlles M. Alpha-1-antitrypsin and other proteinase inhibitors. Curr Opin Pharmacol 2012, 12:309-314.
98. Schmid S.T., Koepke J., Dresel M., Hattesohl A., Frenzel E., Perez J., et al. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2012, 7:687-696.
99. Mohanka M., Khemasuwan D., Stoller J.K. A review of augmentation therapy for alpha-1 antitrypsin deficiency. Expert Opin Biol Ther 2012, 12:685-700.
100. Sclar D.A., Evans M.A., Robison L.M., Skaer T.L. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: Number and costs of years of life gained. Clin Drug Investig 2012, 32:353-360.
101. Stoller J.K., Brantly M. The challenge of detecting alpha-1 antitrypsin deficiency. COPD 2013, 10:26-34.
102. Stockley R.A., Dirksen A., Stolk J. Alpha-1 antitrypsin deficiency: The European experience. COPD 2013, 10:50-53.
103. Wewers M.D., Crystal R.G. Alpha-1 antitrypsin augmentation therapy. COPD 2013, 10:64-67.
104. Strange C. Airway disease in alpha-1 antitrypsin deficiency. COPD 2013, 10:68-73.
105. Campos M.A., Kueppers F., Stocks J.M., Strange C., Chen J., Griffin R., et al. Safety and pharmacokinetics of 120mg/kg versus 60mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: A multicenter, randomized, double-blind, crossover Study (SPARK). COPD 2013, 10:687-695.
106. Monk R., Graves M., Williams P., Strange C. Inhaled alpha 1-antitrypsin: Gauging patient interest in a new treatment. COPD 2013, 10:411-415.
107. Stockley R.A., Miravitlles M., Vogelmeier C. Augmentation therapy for alpha-1 antitrypsin deficiency: Towards a personalised approach. Orphanet J Rare Dis 2013, 8:149.
108. Schünemann H.J., Jaeschke R., Cook D.J., Bria W.F., El-Solh A.A., Ernst A., et al. An official ATS statement: Grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006, 174:605-614. ATS Documents Development and Implementation Committee.
109. Alonso-Coello P., Rigau D., Juliana Sanabria A., Plaza V., Miravitlles M., Martínez L. Calidad y fuerza: el sistema GRADE para la formulación de recomendaciones en las guías de práctica clínica. Arch Bronconeumol 2013, 49:261-267.
110. Guyatt G., Gutterman D., Baumann M.H., Adrizzo-Harris D., Hylek E.M., Phillips B., et al. Grading strength of recommendations and quality of evidence in clinical guidelines: Report from an American Colleg Chest Physicians Task Force. Chest 2006, 129:178-181.
111. Miravitlles M., Soler-Cataluña J.J., Calle M., Molina J., Almagro P., Quintano J.A., et al. Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable. Arch Bronconeumol 2012, 48:247-257.